Search details
1.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Article
in English
| MEDLINE | ID: mdl-38587643
2.
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
Breast Cancer Res Treat
; 196(1): 153-162, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36008651
3.
Posterior Leg Pain: Understanding Soleus Muscle Injuries.
Radiographics
; 42(3): 778-788, 2022.
Article
in English
| MEDLINE | ID: mdl-35427175
4.
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.
Future Oncol
; 2022 Oct 06.
Article
in English
| MEDLINE | ID: mdl-36200668
5.
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Breast Cancer Res
; 23(1): 42, 2021 03 30.
Article
in English
| MEDLINE | ID: mdl-33785053
6.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Article
in English
| MEDLINE | ID: mdl-33152285
7.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31838010
8.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Breast Cancer Res
; 22(1): 45, 2020 05 13.
Article
in English
| MEDLINE | ID: mdl-32404150
9.
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.
Future Oncol
; 16(24): 1801-1813, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32633563
10.
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Eur J Cancer Care (Engl)
; 29(4): e13253, 2020 Jul.
Article
in English
| MEDLINE | ID: mdl-32578279
11.
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Breast Cancer Res
; 21(1): 108, 2019 09 18.
Article
in English
| MEDLINE | ID: mdl-31533777
12.
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.
Oncologist
; 24(5): 603-611, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30710068
13.
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Oncologist
; 24(7): 893-900, 2019 07.
Article
in English
| MEDLINE | ID: mdl-30679318
14.
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Oncologist
; 24(11): e1024-e1033, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31023863
15.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
BMC Med
; 17(1): 8, 2019 01 09.
Article
in English
| MEDLINE | ID: mdl-30621698
16.
Measuring Technique for Meniscal Extrusion Using Ultrasound in the Setting of Posterior Medial Meniscal Root Tears.
Arthrosc Tech
; 13(4): 102916, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38690345
17.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
NPJ Breast Cancer
; 10(1): 20, 2024 Mar 06.
Article
in English
| MEDLINE | ID: mdl-38448600
18.
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
JAMA Oncol
; 10(5): 603-611, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38546612
19.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
EBioMedicine
; 102: 105043, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38447275
20.
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer.
Cancer Treat Rev
; 112: 102496, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36563600